Johnson & Johnson’s (J&J) single-dose vaccine offers strong protection against severe COVID-19, the US Food and Drug Administration (FDA) has confirmed.
According to details, J&J’s Coronavirus vaccine is 66% effective against moderate infection while it is 85% effective against severe infection and does not raise any serious adverse reactions.
ALSO READ
Pakistan Has Lost Nearly $38 Billion Since Being Put on FATF’s Grey List
With this, the FDA is expected to approve J&J’s COVID-19 vaccine for use across the US. If that is the case, J&J’s vaccine will become only the third vaccine to be approved by the FDA.
The other two Coronavirus vaccines have been developed by Moderna and Pfizer which offer 94.1% and 95% protection against symptomatic infection after two doses.
Assuming the FDA will approve J&J’s vaccine for use, the company has claimed that it would roll out 20 million doses by the end of March and additional 100 million doses by the end of summer.
Developed in collaboration with Janssen Pharmaceuticals, J&J’s Coronavirus vaccine is a single-dose vaccine that requires basic refrigeration for storage.
ALSO READ
PIA Increases International Flights and Restores Domestic Flights
It uses an inactivated virus, called an adenovirus, to teach the body’s immune system to recognize and fight off SARS-CoV-2, the Coronavirus that causes COVID-19.
On the other hand, both Moderna and Pfizer Coronavirus vaccines are mRNA-based and consist of two doses each which are administered three to four weeks apart.
While Moderna’s vaccine can be stored at the same temperature as J&J’s vaccine, Pfizer’s vaccine requires to be stored in ultra-cold freezers at temperatures between -80ºC and -60ºC.
